Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report report published on Saturday morning. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of NYSE:BTX traded down $0.11 during midday trading on Friday, hitting $1.73. 1,122 shares of the stock were exchanged, compared to its average volume of 515,543. The business’s 50-day moving average price is $1.86 and its 200 day moving average price is $1.99. The stock has a market capitalization of $101.77 million, a price-to-earnings ratio of -0.76 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12 month low of $0.17 and a 12 month high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.